SOLIGENIX, INC.

Transcripts Soligenix, Inc.

Equities

SNGX

US8342236044

Market Closed - Nasdaq Other stock markets 01:30:01 2024-07-03 pm EDT			5-day change	1st Jan Change
2.26 ^USD	-0.44%		-17.22%	-81.35%

Jun. 25	Soligenix, Inc. Announces Positive Clinical Results from A Comparative Study Evaluating Hybryte?? Against Valchlor®? in the Treatment of Cutaneous T-Cell Lymphoma	CI
May. 23	Sector Update: Health Care Stocks Retreat Late Afternoon	MT

Transcripts

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Transcript : Soligenix, Inc. - Special Call	22-11-29
Transcript : Soligenix, Inc. Presents at Virtual Fall Investor Summit 2020, Nov-17-2020 09:30 AM	20-11-17
Transcript : Soligenix, Inc. Presents at Cantor’s 2020 Global Healthcare Conference, Sep-15-2020 01:20 PM	20-09-15
Transcript : Soligenix, Inc. Presents at MedInvest Infectious Disease and Immunology Investor Conference, Jun-16-2020 02:30 PM	20-06-16

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Protect and grow your investments with the help of our experts

Securing my Investments

fermer